Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index; 9 of the 22 sources its claims cite were checked for support.

Diagnosed prevalence of Ehlers-Danlos syndrome and hypermobility spectrum disorder in Wales, UK: a national electronic cohort study and case–control comparison

Open access

Abstract

Objectives: To describe the epidemiology of diagnosed hypermobility spectrum disorder (HSD) and Ehlers-Danlos syndromes (EDS) using linked electronic medical records. To examine whether these conditions remain rare and primarily affect the musculoskeletal system. Design: Nationwide linked electronic cohort and nested case–control study. Setting: Routinely collected data from primary care and hospital admissions in Wales, UK. Participants: People within the primary care or hospital data systems with a coded diagnosis of EDS or joint hypermobility syndrome (JHS) between 1 July 1990 and 30 June 2017. Main outcome measures: Combined prevalence of JHS and EDS in Wales. Additional diagnosis and prescription data in those diagnosed with EDS or JHS compared with matched controls. Results: We found 6021 individuals (men: 30%, women: 70%) with a diagnostic code of either EDS or JHS. This gives a diagnosed point prevalence of 194.2 per 100 000 in 2016/2017 or roughly 10 cases in a practice of 5000 patients. There was a pronounced gender difference of 8.5 years (95% CI: 7.70 to 9.22) in the mean age at diagnosis. EDS or JHS was not only associated with high odds for other musculoskeletal diagnoses and drug prescriptions but also with significantly higher odds of a diagnosis in other disease categories (eg, mental health, nervous and digestive systems) and higher odds of a prescription in most disease categories (eg, gastrointestinal and cardiovascular drugs) within the 12 months before and after the first recorded diagnosis. Conclusions: EDS and JHS (since March 2017 classified as EDS or HSD) have historically been considered rare diseases only affecting the musculoskeletal system and soft tissues. These data demonstrate that both these assertions should be reconsidered.

Overview

CoChat Summary

TL;DR

In Wales, a linked electronic cohort identified 6021 people with coded EDS/JHS, giving a diagnosed point prevalence of 194.2 per 100 000 in 2016/2017, or roughly 10 cases in a 5000-patient practice. Nested case–control analyses found higher odds of diagnoses and prescriptions across many body systems, not only musculoskeletal, with a pronounced 8.5-year gender difference in mean age at diagnosis.

Key findings

  • The combined cohort contained 6021 distinct individuals (70% women, 30% men): 5064 (84%) coded with JHS and 957 (16%) with EDS. In 2016/2017, 4598 people had an EDS/JHS diagnosis first appearing in primary care (172 per 100 000) and 711 in secondary care (22 per 100 000), yielding a combined diagnosed point prevalence of 194.2 per 100 000.
  • Mean age at diagnosis differed by 8.5 years between men and women (95% CI: 7.70 to 9.22); 72% of men were diagnosed during childhood (<18 years) versus 41% of women. Age at first diagnosis peaked at 5–9 years for men and 15–19 years for women.
  • In the 12 months before and after first coded diagnosis, young people (<18 years) had significantly more additional diagnoses in 16 of 20 Read code disease categories than controls; top odds were musculoskeletal (OR 9.36, 95% CI: 7.98 to 11.00), congenital anomalies (OR 5.89, 95% CI: 3.98 to 8.80) and mental disorders (OR 4.16, 95% CI: 3.29 to 5.27). Adults (≥18 years) also had significantly more diagnoses in 16 of 20 categories; top odds were musculoskeletal (OR 7.95, 95% CI: 6.95 to 9.12), congenital anomalies (OR 5.18, 95% CI: 2.78 to 9.78) and symptoms/signs/ill-defined conditions (OR 2.9, 95% CI: 2.5 to 3.37).
  • Prescription odds were higher in 14 of 17 Read code categories for young people and 15 of 17 for adults. Top prescription categories for young people were musculoskeletal drugs (OR 3.65, 95% CI: 3.18 to 4.18), gastrointestinal drugs (OR 3.02, 95% CI: 2.54 to 3.58) and haematology/dietetic drugs (OR 2.54, 95% CI: 2.06 to 3.11); for adults they were musculoskeletal drugs (OR 5.17, 95% CI: 4.53 to 5.9), central nervous system drugs (OR 3.9, 95% CI: 3.41 to 4.46) and chemotherapy/immunosuppressant drugs (OR 3.03, 95% CI: 1.89 to 4.8).

Methods

  • Nationwide linked electronic cohort and nested case–control study using the Secure Anonymised Information Linkage (SAIL) databank, with routinely collected primary care (Read Version 2) and hospital admissions (ICD-10) data in Wales from 1 July 1990 to 30 June 2017. Primary care data covered about 80% of coded GP information in Wales; Welsh Demographics Service and Patient Episode Database for Wales covered the whole of Wales.
  • Cohort: Welsh residents with a Read Version 2 or ICD-10 diagnostic code of EDS or JHS in primary or secondary care; primary and hospital datasets were combined, duplications identified, and the earliest diagnosis date kept for individuals in both. Prevalence denominators were adjusted for people registered and living in Wales and, for primary care, whose GP practice contributed data to SAIL.
  • Case–control: each case was matched to four controls of the same gender and similar age (within 45 days of the week of birth). Cases and controls required uninterrupted GP registration for 1 year before and after the relevant diagnosis (or died during follow-up), registration with a SAIL-contributing GP, and consistent GP data recording; controls with any diagnosed hereditary connective tissue disorder were excluded. ORs were calculated using Read chapters excluding EDS/JHS codes, and results affecting at least 5 cases or 20 controls were visualised.

Limitations

  • Stated: the study cannot quantify how many people with hEDS or HSD remain undiagnosed, nor comment on the reliability of the diagnoses. Most subjects (89%) were identified via primary care, so studies not using primary care data may underestimate prevalence; data coverage for the first couple of years is less comprehensive; and comparisons were only at Read chapter level.
  • Stated: it is likely that the majority of cases were not actually diagnosed in primary care but had entries created through secondary care contacts, such as outpatient appointments or musculoskeletal assessment clinics, while coded data from those sources are lacking.
  • Evident from the text: the nested case–control cohort was slightly older than the overall cohort (data not shown), and strict selection criteria reduced the number of cases and controls available for analysis; diagnoses were based on coded records without clinical validation, and the study notes possible coding bias during early years of GP computerisation.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1136/bmjopen-2019-031365

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Flow diagram of EDS/JHS cohort and case–control cohort creation. EDS, Ehlers-Danlos syndrome; GP, general practitioner; ICD-10, International Statistical Classification of Diseases and Related Health Problems, 10th Revision; JHS, joint hypermobility syndrome; SAIL, Secure Anonymised Information Linkage
Figure 1 Flow diagram of EDS/JHS cohort and case–control cohort creation. EDS, Ehlers-Danlos syndrome; GP, general practitioner; ICD-10, International Statistical Classification of Diseases and Related Health Problems, 10th Revision; JHS, joint hypermobility syndrome; SAIL, Secure Anonymised Information LinkageCC BY · PubMed Central
Figure 2 Age at first coded diagnosis of EDS/JHS by age group and gender. EDS, Ehlers-Danlos syndrome; JHS, joint hypermobility syndrome.
Figure 2 Age at first coded diagnosis of EDS/JHS by age group and gender. EDS, Ehlers-Danlos syndrome; JHS, joint hypermobility syndrome.CC BY · PubMed Central
Figure 3 Prevalence of coded diagnosis of JHS/EDS in primary care, hospital inpatient and combined over time. EDS, Ehlers-Danlos syndrome; GP, general practitioner; JHS, joint hypermobility syndrome.
Figure 3 Prevalence of coded diagnosis of JHS/EDS in primary care, hospital inpatient and combined over time. EDS, Ehlers-Danlos syndrome; GP, general practitioner; JHS, joint hypermobility syndrome.CC BY · PubMed Central
Figure 4 ORs of Read chapter diagnoses for (A) young people (<18 years of age) and (B) adults (≥18 years of age) within 12 months before and after EDS/JHS diagnosis. Presented are all results that affect at least 5 cases or 20 controls (perinatal conditions, Chapter Q, are not shown as neither young people nor adults had the required minimum number of cases/controls). EDS, Ehlers-Danlos syndrome; JHS, joint hypermobility syndrome.
Figure 4 ORs of Read chapter diagnoses for (A) young people (<18 years of age) and (B) adults (≥18 years of age) within 12 months before and after EDS/JHS diagnosis. Presented are all results that affect at least 5 cases or 20 controls (perinatal conditions, Chapter Q, are not shown as neither young people nor adults had the required minimum number of cases/controls). EDS, Ehlers-Danlos syndrome; JHS, joint hypermobility syndrome.CC BY · PubMed Central
Figure 5 ORs of Read chapter prescriptions for young people (<18 years of age) and adults (≥18 years of age) within 12 months before and after EDS/JHS diagnosis. Presented are all results that affect at least 5 cases or 20 controls (incontinence and stoma appliances, Chapters Q and S, are not shown as neither young people nor adults had the required minimum number of cases/results). EDS, Ehlers-Danlos syndrome; JHS, joint hypermobility syndrome.
Figure 5 ORs of Read chapter prescriptions for young people (<18 years of age) and adults (≥18 years of age) within 12 months before and after EDS/JHS diagnosis. Presented are all results that affect at least 5 cases or 20 controls (incontinence and stoma appliances, Chapters Q and S, are not shown as neither young people nor adults had the required minimum number of cases/results). EDS, Ehlers-Danlos syndrome; JHS, joint hypermobility syndrome.CC BY · PubMed Central

Verification

Claims the paper makes

6 Valid · 1 Not valid · 9 Not checked · 39 Own results and interpretations

15 more claims

Create a free account to see all 55 claims and to verify the 13 references still open.

See all claims — free account
  • Probably not a substantial claim. 20
  • It may state two separate claims as one. 22
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

6 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 41 references

Research works printed but not linked: 1

  1. Grahame, 2006, Joint hypermobility syndrome is highly prevalent in general rheumatology clinics, its occurrence and clinical presentation being gender, age and race-related, Annals of the Rheumatic Diseases, 65, 263

Cited by

See all 274

Metadata

Authors
Demmler, J. C., Atkinson, M. D., Reinhold, E. J., Choy, E., Lyons, R. A., & Brophy, S. T.
Affiliations
  • Swansea University (GB)
  • Royal College of General Practitioners (GB)
  • Cardiff University (GB)
Corresponding author
  • Demmler, Joanne C
  • Reinhold, Emma J
Venue
BMJ Open
Publisher
BMJ
Published
2019-11
Volume
9
Issue
11
Pages
e031365
ISSN
2044-6055 (ISSN-L)
OpenAlex
W2987538608
Cited by
271
References
41
Citations by year
2026: 35 · 2025: 54 · 2024: 59 · 2023: 47 · 2022: 24 · 2021: 39 · 2020: 10 · 2019: 1
FWCI
11.11
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • BMJ Open (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
Medical Research Council (MR/K006525/1, NIWA1)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Connective tissue disorders research
  • Health Sciences › Health Professions › Physical Therapy, Sports Therapy and Rehabilitation › Musculoskeletal pain and rehabilitation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Keywords
Ehlers-Danlos syndrome, hypermobility spectrum disorders, joint hypermobility syndrome, prevalence, rare diseases, musculoskeletal disorders, comorbidities, prescription drug use, age at diagnosis, sex differences, Wales
MeSH terms
Adolescent, Adult, Aged, Child, Ehlers-Danlos Syndrome, Female, Humans, Joint Instability, Male, Medical Record Linkage, Middle Aged, Wales, Prevalence, Case-Control Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diagnosed prevalence of Ehlers-Danlos syndrome and hypermobility spectrum disorder in Wales, UK: a national electronic cohort study and case–control comparison. https://app.cochat.ai/papers/10.1136/bmjopen-2019-031365
The paper
Demmler, J. C., Atkinson, M. D., Reinhold, E. J., Choy, E., Lyons, R. A., & Brophy, S. T. (2019). Diagnosed prevalence of Ehlers-Danlos syndrome and hypermobility spectrum disorder in Wales, UK: a national electronic cohort study and case–control comparison. BMJ Open. https://doi.org/10.1136/bmjopen-2019-031365

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.